%0 Journal Article
%T Estudio del polimorfismo de debrisoquina en una muestra de la poblaci¨®n cubana
%A ¨¢lvarez Corredera
%A Mayra
%A P¨¦rez Hern¨¢ndez
%A B¨¢rbaro
%A Llerena
%A Adri¨¢n
%A Labacena Rodr¨ªguez
%A Mar¨ªa
%A Garc¨ªa Bacallao
%A Lourdes
%A Rojo Hern¨¢ndez
%A Delia
%J Revista Cubana de Farmacia
%D 2005
%I ECIMED
%X the differences in the capacity with which every individual metabolises a drug by a specific route has a clinical relevance for widely used drugs of a narrow safety range if that is the main route in the elimination of the drug, or if the number of therapeutic alternatives is limited; therefore, the pharmacogenetic information is essential in the personalized therapeutics and it contributes to a rational use of drugs. as the cytochrome p4502d6 (cyp2d6) catalyzes more than 65% of the commonly used drugs, the aim of this paper was to identify different cyp2d6 metabolising phenotypes in a sample of 104 subjects of the cuban population by determining the metabolic ratio between urinary concentrations of debrisoquine and its metabolite 4oh-debrisoquine, quantified by high performance liquid chromatography. we found that 3.84% of the individuals studied were slow metabolisers.
%K genetic polymorphism
%K debrisoquine polymorphism
%K cyp2d6.
%U http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S0034-75152005000100005&lng=en&nrm=iso&tlng=en